Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Stephen Machatha, Chief Development Officer of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), sold 22,073 shares of common stock on August 11, 2025. The sales were executed at prices ranging from $5.06 to $5.29, netting approximately $113,713. The transaction comes as the stock shows strong momentum, with a 14% return over the past year and trading near $5.37. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $6 to $13.
The transaction was disclosed in a Form 4 filing with the Securities and Exchange Commission. The filing indicates the sale was to cover tax withholding obligations upon the settlement of time-based restricted stock unit awards. Following the transaction, Machatha directly owns 221,799 shares of Aldeyra Therapeutics, which includes 7,101 shares acquired under the company’s Employee Stock Purchase Plan. The company maintains a healthy balance sheet with more cash than debt and strong liquidity ratios. InvestingPro subscribers can access 8 additional key insights about ALDX’s financial health and growth prospects.
In other recent news, Aldeyra Therapeutics has announced several significant developments that could impact its future. The U.S. Food and Drug Administration (FDA) accepted Aldeyra’s resubmitted New Drug Application for reproxalap, a treatment for dry eye disease, with a PDUFA target action date set for December 16, 2025. This follows a clinical trial that met its primary endpoint of reducing ocular discomfort. In addition, the European Medicines Agency granted Orphan Designation for Aldeyra’s ADX-2191, intended for treating inherited retinal dystrophies, including retinitis pigmentosa.
Furthermore, Aldeyra received a Special Protocol Assessment from the FDA for a clinical trial of its ADX-2191 drug candidate for primary vitreoretinal lymphoma. This trial, set to begin in the second half of 2025, will evaluate cancer cell clearance in patients receiving different dosages. Analyst firm Jones Trading raised its price target for Aldeyra to $9 from $6, maintaining a Buy rating, following the FDA’s acceptance of the reproxalap application. These developments highlight Aldeyra’s ongoing efforts to advance its drug pipeline and secure regulatory approvals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.